Background and Purpose-The DIAS-2 study was the only large, randomized, intravenous, thrombolytic trial that selected patients based on the presence of ischemic penumbra. However, DIAS-2 did not confirm the positive findings of the smaller DEDAS and DIAS trials, which also used penumbral selection. Therefore, a reevaluation of the penumbra selection strategy is warranted. Methods-In post hoc analyses we assessed the relationships of magnetic resonance imaging-measured lesion volumes with clinical measures in DIAS-2, and the relationships of the presence and size of the diffusion-perfusion mismatch with the clinical effect of desmoteplase in DIAS-2 and in pooled data from DIAS, DEDAS, and DIAS-2. Results-In DIAS-2, lesion volumes correlated with National Institutes of Health Stroke Scale (NIHSS) at both baseline and final time points (PϽ0.0001), and lesion growth was inversely related to good clinical outcome (Pϭ0.004). In the pooled analysis, desmoteplase was associated with 47% clinical response rate (nϭ143) vs 34% in placebo (nϭ73; Pϭ0.08). For both the pooled sample and for DIAS-2, increasing the minimum baseline mismatch volume (MMV) for inclusion increased the desmoteplase effect size. The odds ratio for good clinical response between desmoteplase and placebo treatment was 2.83 (95% confidence interval, 1.16 -6.94; Pϭ0.023) for MMV Ͼ60 mL. Increasing the minimum NIHSS score for inclusion did not affect treatment effect size. Key Words: acute cerebral infarction Ⅲ desmoteplase Ⅲ diffusion-weighted imaging Ⅲ magnetic resonance imaging Ⅲ mismatch Ⅲ perfusion Ⅲ stroke Ⅲ thrombolysis R eperfusion of the ischemic penumbra (ie, at-risk but salvageable ischemic brain) is the goal of thrombolytic stroke therapy. Up to 4.5 hours from symptom onset, thrombolytic treatment efficacy is demonstrable in patients with clinical ischemic stroke syndrome. 1,2 Imaging confirmation of the ischemic penumbra has not been required in this treatment period because virtually all patients are assumed to have salvageable tissue in the early period after symptom onset. However, spontaneous recanalization and reperfusion as well as progression of penumbral tissue to infarction occur at variable rates and cannot be predicted by clinical features. After 4.5 hours, many patients may no longer have the target ischemic penumbra that would justify thrombolysis, and their inclusion into clinical trials would confound the detection of therapeutic benefit. A rational approach to expanding the indication for thrombolytic stroke therapy would be selection of only those patients who have evidence of ischemic penumbra. Magnetic resonance imaging (MRI) diffusion-weighted imaging and perfusion-weighted (PWI-DWI) mismatch permits a clinical trial strategy to select patients with ischemic penumbra and to Received October 19, 2011; accepted April 30, 2012 14 were the only acute stroke trials to use prerandomization penumbral imaging as a basis of patient selection. In the absence of either a standard quantitative definition of penumbra by PWI-DWI mismatch or a widely available method to measure prerandomization penumbral volumes within the time constraints of a thrombolytic trial at the time these trials were designed, penumbra was defined as any visually apparent mismatch, which approximately corresponds to a volume perfusion defect at least 20% larger than the volume of acute ischemic DWI abnormality, a volume difference likely to be outside the range of volumetric test-retest variability. 6 The results from the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) and Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) studies using post hoc definitions and quantification of target mismatch volumes suggest that a larger PWI-DWI mismatch size may be a better predictor of good clinical outcome in patients who have early reperfusion when treated with alteplase after 3 hours than a smaller mismatch size. [15] [16] [17] Because those studies did not require mismatch for patient inclusion, the relevance to a trial requiring mismatch selection is unclear.
R eperfusion of the ischemic penumbra (ie, at-risk but salvageable ischemic brain) is the goal of thrombolytic stroke therapy. Up to 4.5 hours from symptom onset, thrombolytic treatment efficacy is demonstrable in patients with clinical ischemic stroke syndrome. 1, 2 Imaging confirmation of the ischemic penumbra has not been required in this treatment period because virtually all patients are assumed to have salvageable tissue in the early period after symptom onset. However, spontaneous recanalization and reperfusion as well as progression of penumbral tissue to infarction occur at variable rates and cannot be predicted by clinical features. After 4.5 hours, many patients may no longer have the target ischemic penumbra that would justify thrombolysis, and their inclusion into clinical trials would confound the detection of therapeutic benefit. A rational approach to expanding the indication for thrombolytic stroke therapy would be selection of only those patients who have evidence of ischemic penumbra. Magnetic resonance imaging (MRI) diffusion-weighted imaging and perfusion-weighted (PWI-DWI) mismatch permits a clinical trial strategy to select patients with ischemic penumbra and to monitor drug effects on the probability of reperfusion and infarct expansion. [3] [4] [5] On MRI, the ischemic penumbra is approximated by a region of mismatch between a larger perfusion defect relative to a smaller region of acute ischemic DWI change, and DWI hyperintensity enlarges and progresses to infarction in the absence of early reperfusion. 6, 7 The use of MRI for patient selection and assessment in thrombolytic stroke trials is supported by evidence that lesion volumes correlate with clinical severity and outcomes [7] [8] [9] and that reperfusion and attenuation of infarct enlargement are markers of recovery in patients treated with alteplase within the clinically proven time window. 10, 11 The clinical trials of the novel thrombolytic desmoteplase (Desmoteplase In Acute Ischemic Stroke [DIAS]), 12 Dose Escalation of Desmoteplase for Acute Ischemic Stroke [DE-DAS], 13 and DIAS-2) 14 were the only acute stroke trials to use prerandomization penumbral imaging as a basis of patient selection. In the absence of either a standard quantitative definition of penumbra by PWI-DWI mismatch or a widely available method to measure prerandomization penumbral volumes within the time constraints of a thrombolytic trial at the time these trials were designed, penumbra was defined as any visually apparent mismatch, which approximately corresponds to a volume perfusion defect at least 20% larger than the volume of acute ischemic DWI abnormality, a volume difference likely to be outside the range of volumetric test-retest variability. 6 The results from the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) and Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) studies using post hoc definitions and quantification of target mismatch volumes suggest that a larger PWI-DWI mismatch size may be a better predictor of good clinical outcome in patients who have early reperfusion when treated with alteplase after 3 hours than a smaller mismatch size. [15] [16] [17] Because those studies did not require mismatch for patient inclusion, the relevance to a trial requiring mismatch selection is unclear.
The phase II DIAS and DEDAS studies enrolled patients with PWI-DWI mismatch for treatment initiated 3 to 9 hours after stroke onset and found that doses of 90 and 125 g/kg desmoteplase compared with placebo had increased rates of both early reperfusion and clinical efficacy at 3 months. 12, 13 The larger phase III DIAS-2 trial enrolled patients with tissue at risk using either the MRI PWI-DWI mismatch or the computed tomography perfusion penumbral pattern. 14 As previously reported, the DIAS-2 trial did not show benefit of desmoteplase in the 3-hour to 9-hour treatment window in the primary intent-to-treat analysis. In contrast to DIAS and DEDAS trials, DIAS-2 observed an unexpectedly high placebo response rate, late non-neurological deaths in the high-dose treatment arm, and the inclusion of patients with milder baseline NIHSS and smaller infarct volumes. 14 The DIAS-2 sample also differed by inclusion of patients selected by computed tomography perfusion, a subgroup with different baseline clinical characteristics and heterogeneous technical features; therefore, pooling of the computed tomography-selected and MRI-selected patients is of questionable validity. As a consequence, it is uncertain to what extent the results of DIAS-2 were attributable to the method of patient selection.
In this further analysis of desmoteplase trial data, we reassessed the use of MRI selection by asking the following questions: (1) 
Materials and Methods

Patients
The DIAS (NCT00638781), DEDAS (NCT00638248), and DIAS-2 (NCT00111852) trials enrolled patients aged 18 to 85 years who had a National Institutes of Health Stroke Scale (NIHSS) score between 4 and 24 points, clinical signs of cerebral hemispheric infarction, and onset of symptoms within 3 to 9 hours. [12] [13] [14] Study personnel and patients were blinded to treatment assignment for the period of the study. Patients received desmoteplase (90 or 125 g/kg) or placebo as 1 intravenous bolus over 1 to 2 minutes. Patients receiving other doses of desmoteplase in DIAS are not included in this analysis because they were not associated with clinical benefit and not used in DIAS-2. The primary efficacy end point required good clinical outcome at day 90 on all 3 outcome scales, predefined as an improvement in NIHSS of Ն8 points from baseline (or NIHSS Յ1), a modified Rankin scale score of 0 to 2 points, and a Barthel index of 75 to 100.
Procedures
The baseline MRI scans from all 3 trials were evaluated qualitatively by an investigator at each site for determination of enrollment eligibility. The presence of mismatch was determined by an investigator in accordance with local practice as an apparent mismatch between the size of acute lesion on DWI and a larger perfusion defect. A central imaging reading group, blinded to treatment assignment and clinical information, subsequently evaluated the imaging data to determine mismatch and core lesion volumes. The core imaging laboratory processed the PWI and DWI images using Stroketool software. Relative mean transit time maps derived from the concentration time curve of the perfusion-weighted magnetic resonance images were calculated by the first moment transit time method. Hypoperfused tissue regions were manually segmented based on hyperintense areas of the mean transit time map to derive the acute hypoperfusion volume. Hyperintense areas of the DWI isotropic map were manually segmented to derive the acute core volume. The difference between hypoperfusion and core volumes at baseline determined the baseline mismatch volume (MMV). Other trial design features were described in the primary reports of the trials. [12] [13] [14] To determine whether the MRI performed as expected in DIAS-2, we investigated imaging to clinical correlations independent of treatment assignment.
Statistical Analysis
Spearman correlations were calculated between baseline core lesion volume and baseline NIHSS score (baseline correlation), and between day 30 core lesion volume and day 90 NIHSS score (outcome correlation). The relationship of change in lesion volume over time with clinical course was investigated using a 2 test comparing lesion growth (yes/no) with good clinical outcome at day 90 (yes/no). The Wilcoxon exact 2-sample test was used to compare change in lesion volume between responders and nonresponders.
In DIAS-2, patients had milder and smaller strokes than those in DIAS and DEDAS; thus, we examined the clinical response to desmoteplase treatment as a function of increasing the minimum baseline MMV for inclusion and as a function of increasing the minimum baseline NIHSS for inclusion. We examined the relationship of baseline PWI-DWI mismatch volume to clinical outcome both in DIAS-2 alone and in the pooled sample of all MRI patients randomized to placebo, 90 g/kg, or 125 g/kg from all 3 desmote-plase trials. In the pooled MRI-selected sample, a logistic regression was performed for clinical response adjusted for treatment group (placebo or desmoteplase), baseline MMV (dichotomized into Յ60 and Ͼ60 mL), and treatment by baseline MMV interaction. The analysis of pooled data was stratified for trial.
To relate the observed proportion of responders in different subgroups, hypothetical sample sizes were calculated using the obtained proportions. It was assumed that comparisons between treatments should be performed using a 2-sided 2 test at the 5% level of significance and with a power of 80%. SAS version 9.1.3 (SAS Institute, Cary, NC) was used for the statistical analysis. PϽ0.05 was considered statistically significant.
Results
DIAS-2 Lesion Volume to Clinical Associations
In the MRI-selected patients in the DIAS-2 trial, baseline core lesion volume significantly correlated to baseline NIHSS (ϭ0.49; PϽ0.0001; nϭ122) and day 30 infarct volume correlated with day 90 NIHSS (ϭ0.56; PϽ0.0001; nϭ106).
There was a significant association of change in core lesion volume from baseline to day 30 with the probability of a favorable clinical response (Pϭ0.004; 2 ; Table 1 ). Among patients with no increase in lesion volume over time, 63% (29/46) had a good clinical outcome. Only 35% (21/60) achieved good outcome when there was an increase in lesion volume over time. The median change in lesion volume among patients with a favorable clinical response was Ϫ1.7 mL and 8.1 mL among nonresponders (PϽ0.0001). Table 2 describes the relationship between the baseline MMV (Յ60 mL and Ͼ60 mL) and the proportion of patients achieving good clinical outcome in DIAS-2. As previously reported for all MRI-selected patients, response rate was 45% with both placebo and desmoteplase. 14 The net difference between the response rate in the placebo and desmoteplase groups increased with greater baseline MMV. In the MRI subgroup, the exclusion of patients with baseline MMV Յ60 mL reduced the clinical responder rate among patients receiving placebo and had a relatively minor impact on the proportion of responders among desmoteplase-treated patients (Table 2) . When MMV were Ͼ60 mL, the clinical effect size of desmoteplase was 14%. Eliminating mild strokes from the sample by increasing the minimum NIHSS requirement did not increase the effect size of desmoteplase on clinical outcome (Table 3) .
Baseline Mismatch and Clinical Response to Desmoteplase in MRI-Selected Patients in DIAS-2
Baseline Mismatch and Clinical Response to Desmoteplase in Pooled DIAS, DEDAS, and DIAS-2 Patient (MRI Subgroup) Samples
Across the 3 trials, 73 patients were randomized to placebo and 143 were randomized to desmoteplase (90 g/kg [nϭ68]; 125 g/kg [nϭ75]). In all patients regardless of MMV, 34% of placebo patients and 47% of desmoteplase-treated patients had a good clinical response ( Table 2 ). The advantage of desmoteplase was greater at larger MMV. At MMV Ͼ60 mL, a 22% higher response rate was observed in the pooled trial data (odds ratio, 2.83; 95% confidence interval, 1.16 -6.94; Pϭ0.023; Table 2 ). There was a trend of statistically significant differences in effect size in Յ60 mL vs Ͼ60 mL baseline mismatch subgroups (Pϭ0.083). Patients with MMV Ͼ60 mL were more likely to demonstrate a desmoteplase clinical response than those with MMV Յ60 mL. A similar trend could not be found when eliminating patients with mild strokes (Table 3) .
Hypothetical Sample Size Requirements for Trials With Mismatch Selection
Assuming the proportions observed in the pooled trial data (47% responders administered desmoteplase vs 34% responders administered placebo), a sample size of 238 PWI-DWI mismatch patients per arm would be required to find significance with 80% power at PϽ0.05 (2-tailed). For patients with MMV Ͼ60 mL (43% responders administered desmoteplase vs 21% responders administered placebo), the sample size requirements would be 70 per arm, consistent with a greater desmoteplase effect in patients with large MMV. 
Discussion
The data from this exploratory analysis of the desmoteplase stroke trials support the hypothesis that selection of patients with PWI-DWI mismatch may distinguish clinical outcomes of thrombolytic treatment from placebo when treatment is initiated 3 to 9 hours from stroke onset. Although any degree of visible mismatch on MRI determined prospectively by the enrolling investigator may be adequate to demonstrate thrombolytic efficacy with a sufficiently large sample size (238 per arm), a larger mismatch volume (Ͼ60 mL) appears to be a more powerful target for thrombolytic trials in the 3-hour to 9-hour window and may require only 70 patients per arm.
The current analysis of DIAS-2 MRI patients confirmed previous findings that the core lesion volumes (from DWI acutely and fluid attenuated inversion recovery at follow-up) correlate to acute and chronic NIHSS scores. [7] [8] [9] The growth in core lesion volume was inversely associated with clinical outcome and smaller lesion growth associated with good outcomes. This observation confirms the MRI clinical associations previously reported. 7, 11, 15, 16 Thus, the MRI in DIAS-2 performed as predicted from previous studies. Whether desmoteplase proves to be a clinically effective thrombolytic in the later time window is the subject of ongoing investigation.
The negative results of DIAS-2 had raised questions about the premise of penumbral imaging selection for thrombolytic trials. Three possible explanations for the difference of DIAS-2 results from those of DIAS and DEDAS included the use of computed tomography penumbral selection, which yielded different patient and lesion characteristics than magnetic resonance penumbral selection, the selection of milder strokes, leading to a higher than expected placebo responder rate, and excess late non-neurological deaths in the active treatment arm of DIAS-2, which may have been attributable to chance alone. The current analyses indicate that although raising the criterion for mismatch severity (ie, volume) brings out a difference in outcomes between desmoteplase-treated patients and placebo (Table 2) , raising the minimum NIHSS requirement does not (Table 3 ). This observation indicates that the tissue biomarker of mismatch size is more directly relevant to thrombolytic selection and outcomes than NIHSS severity. The baseline NIHSS does not indicate whether reperfusion has already occurred, whether a penumbra exists, or whether ischemic injury has progressed to fill-in the ischemic region (match of diffusion and perfusion lesions).
The current analysis suggests that a requirement of a larger mismatch criterion would have overcome the other limitations. Exclusion of patients with milder NIHSS score would not have had a favorable effect on the trial results.
The concept of penumbral selection for thrombolytic and other recanalization therapy has broad support in the literature, which suggests that optimal selection may not be specific for any 1 algorithm for image processing or thresholding. 7, [15] [16] [17] [18] [19] [20] The concept that a larger-than-minimum mismatch may be a more optimal target for reperfusion therapy also has been proposed from a post hoc analysis of the DEFUSE study data. 21 The confirmation of this concept by the desmoteplase trials is important because these trials have been the only ones that required both the diagnosis of PWI-DWI mismatch for inclusion and randomized patients to either thrombolytic or placebo; thus, these results are more directly applicable to future trial design. When first proposed as a marker of the human ischemic penumbra, the PWI-DWI mismatch was defined as any visible difference because the minimum mismatch volume that would be of clinical significance was unknown. 6 Because the test-retest difference of volume measurement rarely exceeded 20%, this magnitude difference has been assumed to be the default mismatch minimum that can be discriminated by qualitative visual assessment. 6, 22 The current analysis indicates that with a large enough sample size, the visually assessed mismatch may be sufficient to demonstrate a clinical benefit of thrombolysis. Although a mismatch volume quantitative estimate of Ͼ60 mL may select a sample with a greater effect size, it is unclear if this can be achieved by qualitative visual estimates. However, recent evidence suggests that qualitative determination of large mismatch selects a comparable sample and yields thrombolytic outcomes comparable with that determined by volumetric measurements. 23 We used the first-moment mean transit time method as an estimate of the perfusion defect because of its known correlations with clinical severity and tissue outcomes, 7, 19, 24, 25 whereas others have preferred other parameters. 15, 16, 21, 24, 26, 27 Although the first moment mean transit time calculation as used in this analysis is relative insensitive to changes in delay thresholds, 25 segmentation by visual appearance of mean transit time abnormality may be unreliable in distinguishing benign oligemia from critical hypoperfusion and likely overestimates the volume of penumbral region. Threshold-based penumbral definitions are a more reliable method to minimize the inclusion of benign oligemia in the estimate of mismatch volume. 15, 16, 28 Future work will examine other commonly used penumbral definitions. Ideally, the method of penumbral selection would be automated, standardized, and immediately available to the enrolling investigator. However, there is no consensus regarding the optimal perfusion parameter, mathematical model for processing perfusion images, or thresholds for identifying the optimal thrombolytic target, although there is an emerging consensus on the principles to follow 29 and progress toward automated immediate determination of mismatch volumes. 28 Alternatives to identifying a large mismatch may be the presence of a middle cerebral artery occlusion 30 or the size of the DWI or PWI lesion, 31 because these also may be predictive of response to thrombolysis. Several limitations and qualifications of this analysis and its interpretation require mention. The identification of the 60-mL threshold to maximize the desmoteplase effect was the result of post hoc exploratory analyses and would require prospective confirmation. The pooling of the 90-g/kg and 125-g/kg groups may obscure dose-related differences, although such differences appeared small at MMV Ͼ60 mL ( Table 2) .
Patient selection by use of perfusion imaging and postprocessing is more demanding on study site personnel, resources, and investigators and introduces an additional source of variability than simpler designs. Although this is a rational approach with promising post hoc data, the advantage of mismatch selection over clinical selection remains to be proven prospectively.
Conclusions
The desmoteplase trials demonstrated that investigatordetermined qualifying mismatch is a feasible and pragmatic approach to mismatch selection. Desmoteplase appears beneficial in patients with large MMV and ineffective in patients with small MMV. Because the desmoteplase trials were the only randomized placebo-controlled thrombolytic trials to use MRI-based penumbral imaging as a selection criterion, these results may be more directly relevant to the design of future trials than analyses based on other samples, and they support the hypothesis that under certain circumstances in highly selected patients the larger PWI-DWI mismatch might be a valid biomarker of the ischemic penumbra for selection into thrombolytic trials at late time windows. 
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